A Double-Blind, Randomized, Parallel-Group Study to Evaluate Long-Term Safety, Tolerability, and Efficacy of a Fixed Dose Combination GSP 301 Nasal Spray Compared With Two Placebo Nasal Spray Formulations in Subjects (Aged 12 Years and Older) With Perennial Allergic Rhinitis (PAR)

Trial Profile

A Double-Blind, Randomized, Parallel-Group Study to Evaluate Long-Term Safety, Tolerability, and Efficacy of a Fixed Dose Combination GSP 301 Nasal Spray Compared With Two Placebo Nasal Spray Formulations in Subjects (Aged 12 Years and Older) With Perennial Allergic Rhinitis (PAR)

Completed
Phase of Trial: Phase III

Latest Information Update: 22 Sep 2017

At a glance

  • Drugs Mometasone/olopatadine (Primary)
  • Indications Perennial allergic rhinitis
  • Focus Adverse reactions; Registrational
  • Sponsors Glenmark Pharmaceuticals S.A.
  • Most Recent Events

    • 18 Sep 2017 Status changed from active, no longer recruiting to completed.
    • 11 Jul 2017 Planned End Date changed from 1 Jun 2017 to 1 Jul 2017.
    • 11 Jul 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Jul 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top